Literature DB >> 18800144

Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.

R Landolfi1, L Di Gennaro, A Falanga.   

Abstract

Thrombophilia, which severely impacts on morbidity and mortality of polycythaemia vera and essential thrombocythaemia, is variably characterized by microcirculatory disturbances, arterial and venous thromboses that often precede disease recognition. Thus, the search for Janus Kinase 2 mutation, the molecular marker of myeloproliferative neoplasms, is becoming increasingly common particularly in patients with vein thromboses at atypical sites. Although the pathogenesis of thrombophilia is still elusive, platelet and leukocyte abnormalities seem particularly critical and likely account for the antithrombotic efficacy of aspirin and hydroxyurea.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18800144     DOI: 10.1038/leu.2008.253

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  31 in total

1.  Pathophysiology of thrombosis in myeloproliferative neoplasms.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro
Journal:  Haematologica       Date:  2011-02       Impact factor: 9.941

2.  Polycythemia vera: gender-related phenotypic differences.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro; Maria Anna Nicolazzi; Igor Giarretta; RosaMaria Marfisi; Roberto Marchioli
Journal:  Intern Emerg Med       Date:  2011-06-10       Impact factor: 3.397

Review 3.  Polycythemia vera.

Authors:  Raffaele Landolfi; Maria Anna Nicolazzi; Angelo Porfidia; Leonardo Di Gennaro
Journal:  Intern Emerg Med       Date:  2010-03-16       Impact factor: 3.397

4.  Laparoscopic hepatectomy in a patient with uncontrolled polycythaemia vera.

Authors:  T R Riekki; E Ling; D Cordovani
Journal:  Anaesth Rep       Date:  2019-12-04

5.  A latent form of essential thrombocythemia presenting as portal cavernoma.

Authors:  Xiao-Yan Cai; Wei Zhou; De-Fei Hong; Xiu-Jun Cai
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

6.  The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera.

Authors:  Lisa Pieri; Costanza Bogani; Paola Guglielmelli; Maria Zingariello; Rosa Alba Rana; Niccolò Bartalucci; Alberto Bosi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

7.  Cerebral Venous Thrombosis and Venous Infarction: Case Report of a Rare Initial Presentation of Smoker's Polycythemia.

Authors:  Mihir Raval; Anu Paul
Journal:  Case Rep Neurol       Date:  2010-11-22

Review 8.  Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.

Authors:  Sara Kalantari; Mardi Gomberg-Maitland
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

9.  JAK2V617F mutation in patients with splanchnic vein thrombosis.

Authors:  Sandra Guerra Xavier; Telma Gadelha; Glicínia Pimenta; Angela Maria Eugenio; Daniel Dias Ribeiro; Fernanda Mendes Gomes; Martin Bonamino; Ilana Renault Zalcberg; Nelson Spector
Journal:  Dig Dis Sci       Date:  2009-08-19       Impact factor: 3.199

10.  Prevalence of venous thromboembolism in patients with secondary polycythemia.

Authors:  Omar Nadeem; Jiang Gui; Deborah L Ornstein
Journal:  Clin Appl Thromb Hemost       Date:  2012-09-23       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.